JCX-4-22 (March 31, 2022)
Estimated Revenue Effects Of H.R. 3617, The “Marijuana Opportunity Reinvestment And Expungement Act (The ‘MORE Act’),” Scheduled For Consideration By The House Of Representatives On April 1, 2022 (Rules Committee Print 117-37, As Reported By The Committee On The Judiciary, With Modifications)
The staff of the Joint Committee on Taxation has prepared estimates of the revenue effects of H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act (the “MORE Act”).
The staff of the Joint Committee on Taxation has prepared estimates of the revenue effects of H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act (the “MORE Act”).
Related Publications
-
JCX-9R-23 (May 22, 2023)
Overview Of The Federal Tax System As In Effect For 2023
view details -
JCX-8-23 (May 09, 2023)
Present Law And Economic Background Relating To Pharmaceutical Manufacturers And U.S. International Tax Policy
view details -
JCX-7-23 (April 26, 2023)
Estimated Revenue Effects Of Division A, Title III Of H.R. 2811, The "Limit, Save, Grow Act Of 2023
view details